– Form 8 Filing
Canaccord Genuity Maintains Buy on Salesforce, Lowers Price Target to $180
Canaccord Genuity analyst David Hynes maintains Salesforce (NYSE:CRM) with a Buy and lowers the price target from $215 to $180.
Biocept Inc Lowering Headcount By More Than 40% From Our Pre-Covid-19 Testing Level
– Form 8 Filing
Related Posts
SOFIE And GE HealthCare Enter Licensing Agreement To Develop FAP PET Radiotracers
A global licensing agreement has been signed for the development and commercialization of SOFIE's two investigational Gallium-68 and Fluorine-18 Fibroblast Activation Protein Inhibitors (FAPI) radiopharmaceutical
Inuvo Q3 EPS $(0.03) Misses $(0.01) Estimate, Sales $17.07M Miss $22.05M Estimate
Inuvo (AMEX:INUV) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.01) by 200 percent. This is a 50 percent decrease over losses of $(0.02) per share from the same period
Crypto Analyst Benjamin Cowen Warns of Summer Correction Amid Bitcoin Dip
A popular crypto analyst has issued a warning to investors, suggesting that the Federal Reserve’s monetary policy decisions could significantly impact the cryptocurrency market in the coming months.